ClinicalTrials.gg
CompletedNCT02348489Updated Aug 27, 2024Results posted

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

A Phase 3 interventional study of SGI-110 (guadecitabine) and Treatment Choice in Leukemia, Myeloid, Acute, sponsored by Astex Pharmaceuticals, Inc.. Completed at 135 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
815
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. — 4 open to participants now, 6 under way, 2 of them phase 3. Leukemia, Myeloid, Acute · Otsuka Holdings Co., Ltd..

Enrollment
Largest of 20
815 · median 42
Started
2015
with 1 other
Phase 3
4 of 20
none open now
Registered
7th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., this one has the largest enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 7th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.

03

Conditions studied

  • Leukemia, Myeloid, Acute

Keywords

  • AML
  • Acute Myeloid Leukemia
  • SGI-110
  • DNA Hypomethylating Agen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

or histologically confirmed diagnosis of AML (except M3 acute promyelocytic leukemia) according to World Health Organization (WHO) classification.

Performance status () of 0-3. Adults with previously untreated AML except for hydroxyurea or . Prior hydroxyurea or lenalidomide treatment for myelodysplastic syndrome (MDS) is allowed.

Not considered candidates for intensive remission induction chemotherapy at time of enrollment based on EITHER:

  1. ≥75 years of age OR
  2. \<75 years of age with at least 1 of the following:

i. Poor performance status (ECOG) score of 2-3.

ii. heart or lung comorbidities, as reflected by at least 1 of:

  1. (LVEF) ≤50%.
  2. Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected.
  3. (FEV1) ≤65% of expected.
  4. Chronic stable angina or congestive heart failure controlled with medication.

iii. Liver transaminases >3 × (ULN).

iv. Other (s) to anthracycline therapy (must be documented).

v. Other comorbidity the investigator judges incompatible with intensive remission induction chemotherapy, which must be documented and approved by the study medical monitor before randomization.

as estimated by the Cockcroft-Gault (C-G) or other medically acceptable formulas ≥30 mL/min.

Exclusion criteria

Exclusion Criteria:

Candidate for intensive remission induction chemotherapy at the time of enrollment.

Candidate for best supportive care only, ie, not a candidate for any active therapy with the TC comparators.

Known extramedullary central nervous system (CNS) AML.

Second currently requiring active therapy except breast or prostate cancer stable on or responding to endocrine therapy.

Prior treatment with decitabine or azacitidine.

to decitabine, SGI-110, or SGI-110 .

Known active (HIV), virus (HBV), or virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.

Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol.

congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or advanced pulmonary disease requiring >2 liters per minute (LPM) oxygen.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
815 participants (actual)

Study arms

  • Experimental
    SGI-110 (guadecitabine)

    Guadecitabine 60 mg/m\^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.

    Drug: SGI-110 (guadecitabine)

  • Active comparator
    Treatment Choice

    One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m\^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m\^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.

    Drug: Treatment Choice

Interventions

  • Investigational medicinal product

  • DrugTreatment Choice

    Choice of one: cytarabine, decitabine, or azacitidine

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Complete Response (CR)

    Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist.

    Time frame: Up to 38 months (median follow-up of 25.5 months)

  2. Overall Survival

    Survival time was defined as the number of days from the day the participant was randomly assigned to study treatment to the date of death, regardless of cause.

    Time frame: At 676 death events (up to 38 months)

Secondary outcomes

  1. Number of Participants With Composite CR (CRc)

    CRc is reported as the number of participants with a best response of CR, complete response with incomplete platelet recovery (CRp), or complete response with incomplete blood count recovery (CRi).

    Time frame: Up to 38 months (median follow-up of 25.5 months)

  2. Number of Days Alive and Out of the Hospital

    The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The Number of Days Alive and Out of the Hospital (NDAOH) was calculated as: NDAOH=180 - total duration of all hospital stays within 180 days from the first treatment - number of death days before Day 180. For subjects who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the subject would have died the day after the last contact day.

    Time frame: Month 6

  3. Progression-free Survival (PFS)

    Progression-free survival was defined as the number of days from randomization to the earliest date of investigator's assessment of disease progression, participant receiving an alternative anti-leukemia therapy (including hematopoietic cell transplant), or relapse by peripheral blood (PB) assessment or blinded bone marrow (BM) assessment, whichever occurred first, or death, regardless of cause.

    Time frame: Up to 38 months (median follow-up of 25.5 months)

  4. Number of Red Blood Cell or Platelet Transfusions

    The total number of red blood cells (RBCs) transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit.

    Time frame: Month 6

  5. Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-5D-5L

    EuroQol 5-level 5-dimension (EQ-5D-5L) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. Scores within each dimension for EQ-5D (mobility, self-care, usual activity, pain/discomfort, anxiety/depression) were calculated using counts and proportions. Mean change in scores from baseline are summarized in which an index score of 0 represents the worst health state and 1 represents the best health state.

    Time frame: Baseline to Month 6

  6. Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-VAS

    EuroQol-Visual Analogue Scale (EQ-VAS) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. A vertical 20-cm scale for EQ-VAS was used where the lowest value of 0 was labeled "the worst health you can imagine" and the top value of 100 was labeled "the best health you can imagine." Mean change in scores from baseline are summarized.

    Time frame: Baseline to Month 6

  7. Duration of CR

    Duration of CR (in number of days) was calculated from the first time a CR was observed to the time of relapse, defined as the earliest time point whereby BM assessment or PB assessment indicated relapse/disease progression due to reappearance of leukemic blasts in PB or ≥ 5% leukemic blasts in BM.

    Time frame: Up to 38 months (median follow-up of 25.5 months)

07

Results

Posted Jan 14, 2021

Participant flow

A total of 949 participants were assessed for inclusion in the study. Of these, 134 participants failed screening assessments and 815 participants were randomized.

Participant flow — Overall Study
MilestoneSGI-110 (Guadecitabine)Treatment Choice
Started408407
Completed5540
Not completed353367
Withdrew: Death336335
Withdrew: Withdrawal by subject1427
Withdrew: Lost to follow-up35

Outcome measures

PrimaryNumber of Participants With a Complete Response (CR)

Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist.

Time frame:
Up to 38 months (median follow-up of 25.5 months)
Reported as:
Count of participants · Participants
Number of Participants With a Complete Response (CR)
ParticipantsSGI-110 (Guadecitabine)Treatment Choice
Number of Participants With a Complete Response (CR)7971
Statistical analysis
  • SGI-110 (Guadecitabine) vs Treatment Choice · Cochran-Mantel-Haenszel · p = 0.482 · Difference in response rate (%): 1.92 · 96% CI -3.67 to 7.5
PrimaryOverall Survival

Survival time was defined as the number of days from the day the participant was randomly assigned to study treatment to the date of death, regardless of cause.

Time frame:
At 676 death events (up to 38 months)
Reported as:
Median · days
Overall Survival
daysSGI-110 (Guadecitabine)Treatment Choice
Overall Survival213 (187 to 255)254 (223 to 282)
Statistical analysis
  • SGI-110 (Guadecitabine) vs Treatment Choice · Stratified log-rank · p = 0.7328 · Hazard ratio (hr): 0.97 · 95% CI 0.83 to 1.14
SecondaryNumber of Participants With Composite CR (CRc)

CRc is reported as the number of participants with a best response of CR, complete response with incomplete platelet recovery (CRp), or complete response with incomplete blood count recovery (CRi).

Time frame:
Up to 38 months (median follow-up of 25.5 months)
Reported as:
Count of participants · Participants
Number of Participants With Composite CR (CRc)
ParticipantsSGI-110 (Guadecitabine)Treatment Choice
Number of Participants With Composite CR (CRc)9391
SecondaryNumber of Days Alive and Out of the Hospital

The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The Number of Days Alive and Out of the Hospital (NDAOH) was calculated as: NDAOH=180 - total duration of all hospital stays within 180 days from the first treatment - number of death days before Day 180. For subjects who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the subject would have died the day after the last contact day.

Time frame:
Month 6
Reported as:
Mean · days
Number of Days Alive and Out of the Hospital
daysSGI-110 (Guadecitabine)Treatment Choice
Number of Days Alive and Out of the Hospital98.1 ± 63.6105.7 ± 63.58
SecondaryProgression-free Survival (PFS)

Progression-free survival was defined as the number of days from randomization to the earliest date of investigator's assessment of disease progression, participant receiving an alternative anti-leukemia therapy (including hematopoietic cell transplant), or relapse by peripheral blood (PB) assessment or blinded bone marrow (BM) assessment, whichever occurred first, or death, regardless of cause.

Time frame:
Up to 38 months (median follow-up of 25.5 months)
Reported as:
Median · days
Progression-free Survival (PFS)
daysSGI-110 (Guadecitabine)Treatment Choice
Progression-free Survival (PFS)159 (136 to 178)166 (148 to 179)
SecondaryNumber of Red Blood Cell or Platelet Transfusions

The total number of red blood cells (RBCs) transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit.

Time frame:
Month 6
Reported as:
Mean · transfusion units
Number of Red Blood Cell or Platelet Transfusions
transfusion unitsSGI-110 (Guadecitabine)Treatment Choice
Red Blood Cell Transfusions16.2 ± 11.8415.6 ± 13.02
Platelet Transfusions12.5 ± 18.7814.4 ± 39.10
SecondaryChange in Health-related Quality of Life (QOL) Scores From Baseline: EQ-5D-5L

EuroQol 5-level 5-dimension (EQ-5D-5L) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. Scores within each dimension for EQ-5D (mobility, self-care, usual activity, pain/discomfort, anxiety/depression) were calculated using counts and proportions. Mean change in scores from baseline are summarized in which an index score of 0 represents the worst health state and 1 represents the best health state.

Time frame:
Baseline to Month 6
Reported as:
Mean · score on a scale
Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-5D-5L
score on a scaleSGI-110 (Guadecitabine)Treatment Choice
Baseline0.7767 ± 0.21600.7663 ± 0.2291
Month 60.8252 ± 0.18250.8240 ± 0.1948
Change from Baseline-0.0023 ± 0.18300.0112 ± 0.2325
SecondaryChange in Health-related Quality of Life (QOL) Scores From Baseline: EQ-VAS

EuroQol-Visual Analogue Scale (EQ-VAS) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. A vertical 20-cm scale for EQ-VAS was used where the lowest value of 0 was labeled "the worst health you can imagine" and the top value of 100 was labeled "the best health you can imagine." Mean change in scores from baseline are summarized.

Time frame:
Baseline to Month 6
Reported as:
Mean · score on a scale
Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-VAS
score on a scaleSGI-110 (Guadecitabine)Treatment Choice
Baseline64.64 ± 21.6963.58 ± 21.05
Month 672.76 ± 18.6171.72 ± 18.88
Change from Baseline3.28 ± 19.353.67 ± 22.16
SecondaryDuration of CR

Duration of CR (in number of days) was calculated from the first time a CR was observed to the time of relapse, defined as the earliest time point whereby BM assessment or PB assessment indicated relapse/disease progression due to reappearance of leukemic blasts in PB or ≥ 5% leukemic blasts in BM.

Time frame:
Up to 38 months (median follow-up of 25.5 months)
Reported as:
Median · days
Duration of CR
daysSGI-110 (Guadecitabine)Treatment Choice
Duration of CR217 (175 to 261)231 (182 to 289)

Adverse events

Collected over Up to 51 months. Median (range) duration of treatment was 5 cycles (1-42) for SGI-110 and 5 cycles (1-37) for Treatment Choice (28 days per cycle). Treatment-emergent adverse events were events that first occurred or worsened after the first dose of study treatment until 30 days after the last dose or start of an alternative anti-leukemia treatment, whichever occurred first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SGI-110 (Guadecitabine)341/408 (83.6%)327/401 (81.5%)379/401 (94.5%)
Treatment Choice344/407 (84.5%)297/392 (75.8%)371/392 (94.6%)
Most frequent serious events
Showing 10 of 379
Most frequent serious events
EventSGI-110 (Guadecitabine)Treatment Choice
PneumoniaInfections and infestations117/40179/392
Febrile neutropeniaBlood and lymphatic system disorders101/40188/392
SepsisInfections and infestations62/40144/392
Septic shockInfections and infestations16/40117/392
PyrexiaGeneral disorders16/40113/392
Acute kidney injuryRenal and urinary disorders11/40115/392
ThrombocytopeniaBlood and lymphatic system disorders15/4015/392
Urinary tract infectionInfections and infestations14/40110/392
Cardiac failureCardiac disorders8/40110/392
General physical health deteriorationGeneral disorders9/40110/392
Most frequent other events
Showing 10 of 57
Most frequent other events
EventSGI-110 (Guadecitabine)Treatment Choice
ConstipationGastrointestinal disorders125/401114/392
DiarrheaGastrointestinal disorders122/40183/392
ThrombocytopeniaBlood and lymphatic system disorders116/401101/392
NeutropeniaBlood and lymphatic system disorders115/40188/392
PyrexiaGeneral disorders89/401110/392
NauseaGastrointestinal disorders91/401108/392
HypokalemiaMetabolism and nutrition disorders96/40177/392
Edema peripheralGeneral disorders95/40178/392
Decreased appetiteMetabolism and nutrition disorders89/40162/392
AnemiaBlood and lymphatic system disorders88/40178/392

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)SGI-110 (Guadecitabine)Treatment ChoiceTotal
Mean75.9 ± 6.275.9 ± 5.875.9 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)SGI-110 (Guadecitabine)Treatment ChoiceTotal
Female177165342
Male231242473
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SGI-110 (Guadecitabine)Treatment ChoiceTotal
Hispanic or Latino151429
Not Hispanic or Latino365345710
Unknown or Not Reported284876
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SGI-110 (Guadecitabine)Treatment ChoiceTotal
American Indian or Alaska Native011
Asian7174145
Native Hawaiian or Other Pacific Islander202
Black or African American9514
White311291602
More than one race011
Unknown or Not Reported153550
08

Study locations

135 sites
  • Mayo Clinic Cancer Center
    Scottsdale, Arizona 85259-5499, United States
  • Scripps Cancer Center
    La Jolla, California, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66160, United States
  • University of Minnesota Medical Center
    Minneapolis, Minnesota 55454, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • John Theurer Cancer Center at Hackensack
    Hackensack, New Jersey 07601, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87131, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10065, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11790, United States
  • Duke Cancer Center
    Durham, North Carolina, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • University Hospitals Monarch Medical Center
    Cleveland, Ohio, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Temple University
    Philadelphia, Pennsylvania 19111, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Austin Health
    Heidelberg, Victoria, Australia
  • Medizinische Universität Graz
    Graz, Styria, Austria
  • Hanusch Krankenhaus Wiener Gebietskrankenkasse
    Wien, Vienna, Austria
  • Grand Hôpital de Charleroi
    Charleroi, Hainaut 6061, Belgium
  • UZ Gent
    Ghent, Oost-vlaanderen 9000, Belgium
  • Algemeen Ziekenhuis Sint-Jan
    Brugge, West-vlaanderen 8000, Belgium
  • UMHAT 'Sveti Georgi' EAD
    Plovdiv, Bulgaria
  • Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD
    Varna, Bulgaria
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Hospital
    Edmonton, Alberta 76B 2B7, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
  • Fakultní nemocnice Brno
    Brno, Jihormoravsky KRAJ, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Praha 2, Praha, Czechia
  • Fakultní nemocnice Královské Vinohrady
    Praha 10, Praha 10, Czechia
  • Aarhus University Hospital
    Aarhus, 8000, Denmark
  • Rigshospitalet-Copenhagen University Hospital
    Copenhagen, Denmark
  • Odense University Hospital
    Odense, Denmark
  • Tampere University Hospital
    Tampere, Southern Finland, Finland
  • Helsinki University Central Hospital
    Helsinki, Finland
  • GHR Mulhouse Sud-Alsace
    Mulhouse Cedex, Alsace, France
  • Hôpital Hôtel-Dieu
    Bayonne, Aquitaine, France
  • Centre Henri-Becquerel
    Rouen Cedex 1, Haute-normandie, France
  • Hôpital Saint Louis
    Paris Cedex 10, Ile-de-france 75010, France
  • CHRU de Limoges - Hôpital Dupuytren
    Limoges Cedex, Limousin, Lorraine 87000, France
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse cedex 9, Midi-pyrenees, France
  • Hôpital Hôtel-Dieu
    Nantes cedex 1, PAYS DE LA Loire, France
  • Institut Paoli Calmettes
    Marseille Cedex 9, Provence Alpes COTE D'azur, France
  • Centre Antoine Lacassagne
    Nice, Provence Alpes COTE D'azur, France
  • Centre Hospitalier Universitaire Grenoble
    La Tronche, Rhone-alpes 38700, France
  • Centre Léon Bérard
    Lyon Cedex 08, Rhone-alpes, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite Cedex, Rhone-alpes, France
  • Universitaetsklinikum Freiburg
    Freiburg, Baden-wuerttemberg, Germany
  • Universitätsklinikum Ulm
    Ulm, Baden-wuerttemberg, Germany
  • Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
    Villingen-Schwenningen, Baden-wuerttemberg, Germany
  • Universitätsklinikum Frankfurt Goethe Universität
    Frankfurt am Main, Hessen, Germany
  • Städtisches Klinikum Braunschweig gGmbH
    Braunschweig, Niedersachsen 38114, Germany
  • Marien Hospital Düsseldorf GmbH
    Düsseldorf, Nordrhein-westfalen, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Schleswig-holstein, Germany
  • Bacs-Kiskun Megyei Korhaz
    Kecskemét, Bacs-kiskun, Hungary
  • Semmelweis Egyetem
    Budapest, 1085, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, 7400, Hungary
  • Azienda Ospedaliera Ospedali Riuniti Marche Nord
    Pesaro, Pesaro E Urbino, Italy
  • IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
    Rionero in Vulture, Potenza, Italy
  • Azienda Ospedaliero-Univesitaria San Luigi Gonzaga
    Orbassano, Torino, Italy
  • Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
    Alessandria, Italy
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, Italy
  • Azienda Ospedaliera Ospedale di Busto Arsizio
    Busto Arsizio, 21052, Italy
  • Azienda Ospedaliera-Universitaria Vittorio Emanuele-Ferrarotto-Santo Bambino
    Catania, Italy
  • IRCCS Azienda Ospedaliera Universitaria San Martino - IST
    Genova, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milano, Italy
  • Azienda Ospedaliero-Universitaria Policlinico di Modena
    Modena, Italy
  • AORN A. Cardarelli
    Napoli, Italy
  • Azienda Policlinico Umberto I di Roma
    Roma, Italy
  • Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine
    Udine, Italy
  • Chubu, Japan
  • Chugoku, Japan
  • Kanto, Japan
  • Kinki, Japan
  • Kyushu, Japan
  • Tohoku, Japan
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Hwasun, Jeollanam-do, Korea, Republic of
  • Seoul National University Hospital
    Jongno Gu, Seoul, Korea, Republic of
  • Inje University Busan Paik Hospital
    Busan, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul Saint Mary's Hospital
    Seoul, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, Korea, Republic of

Showing the first 100 of 135 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in May 2018, 38 months.

Results were first posted in Jan 2021, 2 years 7 months after primary completion. A results delay was requested in Nov 2018.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 38 months is close to that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2015
First posted
Jan 28, 2015
StartActual
Mar 19, 2015
Primary completionActual
May 31, 2018
CompletionActual
Jun 17, 2019
Results delay requested
Nov 13, 2018
Results first posted
Jan 14, 2021
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348489
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
Mar 19, 2015
Primary completion
May 31, 2018
Completion
Jun 17, 2019
Results posted
Jan 14, 2021
Last update
Aug 27, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guadecitabine

Start the discussion